Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Dexamethasone 16mg/5ml oral liquid
0603020G0AABKBK
|
Dexamethasone (Systemic) | Dexamethasone | Endocrine System | No data available |
|
Dexamethasone 1mg/5ml oral liquid
0603020G0AABJBJ
|
Dexamethasone (Systemic) | Dexamethasone | Endocrine System | No data available |
|
Dexamethasone 2.5mg/5ml oral liquid
0603020G0AABQBQ
|
Dexamethasone (Systemic) | Dexamethasone | Endocrine System | No data available |
|
Dexamethasone 200micrograms/5ml oral liquid
0603020G0AACCCC
|
Dexamethasone (Systemic) | Dexamethasone | Endocrine System | No data available |
|
Dexamethasone 20mg/5ml oral liquid
0603020G0AABVBV
|
Dexamethasone (Systemic) | Dexamethasone | Endocrine System | No data available |
|
Dexamethasone 250micrograms/5ml oral liquid
0603020G0AABTBT
|
Dexamethasone (Systemic) | Dexamethasone | Endocrine System | No data available |
|
Dexamethasone 3mg/5ml oral liquid
0603020G0AABWBW
|
Dexamethasone (Systemic) | Dexamethasone | Endocrine System | No data available |
|
Dexamethasone 400microgram capsules
0603020G0AACECE
|
Dexamethasone (Systemic) | Dexamethasone | Endocrine System | No data available |
|
Dexamethasone 4mg/5ml oral liquid
0603020G0AAA8A8
|
Dexamethasone (Systemic) | Dexamethasone | Endocrine System | No data available |
|
Dexamethasone 6mg/5ml oral liquid
0603020G0AABNBN
|
Dexamethasone (Systemic) | Dexamethasone | Endocrine System | No data available |
|
Dexamethasone 8mg/5ml oral liquid
0603020G0AAA9A9
|
Dexamethasone (Systemic) | Dexamethasone | Endocrine System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.